戻る Agenda
Capital Efficient Drug Development with Revolutionary Technologies: Calculated Risks
Session Chair(s)
Robert Wright, MBA
Chief Editor
Life Science Connect, United States
Being willing to take risks is essential to innovation. Calculated risk involves considerable analysis and market understanding but also requires passion, guts, perseverance, and constant reassessment and willingness to change course. This session will address how life science leaders must focus on practical translation of the science while being mindful of the convergence of multiple disciplines like ethics, information technology, and economics.
Learning Objective : Define calculated risk; Describe potential roadblocks to bringing a disruptive technology to the market; Outline key decisions that mitigate risk and allow you to advance in a capital efficient manner.
Speaker(s)
Build It and They Will Come, Won't They?
Leslie J. Williams
ImmusanT, United States
Director, Founder, President and Chief Executive Officer
Tale of Two Pharmas
Keith Murphy
Organovo, Inc., United States
Chairman and Chief Executive Officer
Plans, People and Process
Laurie A. Halloran, BSN, MS
United States
President and Chief Executive Officer